Grandfield & Dodd LLC Makes New Investment in Danaher Corporation $DHR

Grandfield & Dodd LLC purchased a new stake in Danaher Corporation (NYSE:DHR) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 12,620 shares of the conglomerate’s stock, valued at approximately $2,404,000.

Several other large investors have also recently added to or reduced their stakes in DHR. BlackRock Inc. acquired a new stake in Danaher in the 2nd quarter worth about $10,492,520,000. State Street Corp increased its stake in shares of Danaher by 1.7% in the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after purchasing an additional 472,608 shares during the last quarter. Capital International Investors raised its stake in Danaher by 8.9% during the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after acquiring an additional 1,487,768 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Danaher by 9.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock valued at $3,656,595,000 after purchasing an additional 1,334,221 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after purchasing an additional 1,517,904 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on DHR. HSBC cut their price objective on Danaher from $270.00 to $230.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Guggenheim cut their price target on Danaher from $235.00 to $200.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. JPMorgan Chase & Co. reduced their target price on shares of Danaher from $275.00 to $245.00 and set an “overweight” rating for the company in a research note on Wednesday, April 22nd. Weiss Ratings raised Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, July 15th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $228.91.

Danaher Stock Performance

Shares of DHR opened at $202.44 on Tuesday. The stock’s 50-day simple moving average is $193.52 and its 200 day simple moving average is $192.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The stock has a market capitalization of $142.31 billion, a price-to-earnings ratio of 35.96, a price-to-earnings-growth ratio of 2.52 and a beta of 0.78.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.77 earnings per share. Research analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.